A196170 Stock Overview
A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ALTEOGEN Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩292,000.00 |
| 52 Week High | ₩455,500.00 |
| 52 Week Low | ₩66,100.00 |
| Beta | 1.15 |
| 11 Month Change | -23.26% |
| 3 Month Change | -7.30% |
| 1 Year Change | 294.06% |
| 33 Year Change | 398.44% |
| 5 Year Change | 2,006.61% |
| Change since IPO | 9,678.60% |
Recent News & Updates
ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution
May 25
ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?
Feb 29Recent updates
ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution
May 25ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?
Feb 29ALTEOGEN Inc.'s (KOSDAQ:196170) Has Found A Path To Profitability
Apr 13Is Weakness In ALTEOGEN Inc. (KOSDAQ:196170) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Feb 18
Do Insiders Own Lots Of Shares In ALTEOGEN Inc. (KOSDAQ:196170)?
Dec 27Shareholder Returns
| A196170 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -33.3% | -4.5% | 2.4% |
| 1Y | 294.1% | 21.1% | -4.0% |
Return vs Industry: A196170 exceeded the KR Biotechs industry which returned 21.1% over the past year.
Return vs Market: A196170 exceeded the KR Market which returned -4% over the past year.
Price Volatility
| A196170 volatility | |
|---|---|
| A196170 Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A196170's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A196170's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 145 | Soon-Jae Park | www.alteogen.com |
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer.
ALTEOGEN Inc. Fundamentals Summary
| A196170 fundamental statistics | |
|---|---|
| Market cap | ₩15.56t |
| Earnings (TTM) | -₩1.28b |
| Revenue (TTM) | ₩90.79b |
171.4x
P/S Ratio9,999x
P/E RatioIs A196170 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A196170 income statement (TTM) | |
|---|---|
| Revenue | ₩90.79b |
| Cost of Revenue | ₩56.31b |
| Gross Profit | ₩34.48b |
| Other Expenses | ₩35.76b |
| Earnings | -₩1.28b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -24.06 |
| Gross Margin | 37.98% |
| Net Profit Margin | -1.41% |
| Debt/Equity Ratio | 4.1% |
How did A196170 perform over the long term?
See historical performance and comparison